Soligenix Files Definitive Proxy Statement for June 20, 2025 Meeting
Ticker: SNGX · Form: DEF 14A · Filed: May 5, 2025 · CIK: 812796
| Field | Detail |
|---|---|
| Company | Soligenix, Inc. (SNGX) |
| Form Type | DEF 14A |
| Filed Date | May 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
TL;DR
SOLIGENIX proxy filed, shareholder vote on June 20th. Directors up for election.
AI Summary
Soligenix, Inc. filed its definitive proxy statement on May 5, 2025, for its annual meeting of stockholders scheduled for June 20, 2025. The filing outlines the proposals to be voted on by shareholders, including the election of directors and other corporate governance matters. Soligenix, Inc. is a pharmaceutical preparations company incorporated in Delaware.
Why It Matters
This filing is crucial for shareholders as it details the agenda for the upcoming annual meeting, allowing them to make informed decisions on company leadership and governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial information or material events.
Key Players & Entities
- SOLIGENIX, INC. (company) — Registrant
- 20250620 (date) — Annual Meeting Date
- 20250505 (date) — Filing Date
- DOR BIOPHARMA INC (company) — Former Company Name
- ENDOREX CORP (company) — Former Company Name
- IMMUNOTHERAPEUTICS INC (company) — Former Company Name
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with the definitive proxy statement for Soligenix, Inc.'s annual meeting of stockholders.
When is the annual meeting of stockholders scheduled to take place?
The annual meeting of stockholders is scheduled to take place on June 20, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on May 5, 2025.
What is the primary business of Soligenix, Inc. according to the filing?
Soligenix, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Has Soligenix, Inc. operated under any previous names?
Yes, Soligenix, Inc. has operated under the former names DOR BIOPHARMA INC, ENDOREX CORP, and IMMUNOTHERAPEUTICS INC.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 5, 2025 regarding SOLIGENIX, INC. (SNGX).